Share on StockTwits

Jefferies Group hoisted their price objective on shares of GlaxoSmithKline plc (LON:GSK) from GBX 1,520 ($25.64) to GBX 1,585 ($26.74) in a research note issued on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s target price would suggest a potential downside of 1.74% from the stock’s previous close.

A number of other firms have also recently commented on GSK. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, May 2nd. They now have a GBX 1,755 ($29.61) price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Thursday, May 1st. They now have a GBX 1,600 ($26.99) price target on the stock. Finally, analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline plc from GBX 1,750 ($29.52) to GBX 1,660 ($28.00) in a research note on Thursday, May 1st. They now have a “hold” rating on the stock. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of GBX 1,713.53 ($28.91).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1612.9999 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 556.50 and a one year high of GBX 2076.00. The stock has a 50-day moving average of GBX 1603. and a 200-day moving average of GBX 1618.. The company’s market cap is £77.650 billion.

The company also recently announced a dividend, which is scheduled for Thursday, July 10th. Investors of record on Wednesday, May 14th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.17%. The ex-dividend date is Wednesday, May 14th.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.